Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Peptidream Inc (PPTDF)

Peptidream Inc (PPTDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PPTDF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.1100 unch
on 04/30/24
13.1130 -0.02%
on 04/30/24
N/A (+38.00%)
since 03/22/24
3-Month
8.5600 +53.15%
on 02/14/24
13.1130 -0.02%
on 04/30/24
+4.5500 (+53.15%)
since 12/01/23

Most Recent Stories

More News
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting

Proof-of-Concept Data Demonstrates Broad Therapeutic Potential of Company’s Multi-targeted Antibody Therapy Enhancer (MATE™) Platform

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting

NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies,...

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE™) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting

NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies,...

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals Announces Data Presentation on Novel Conjugation Platform at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting

NEW HAVEN, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies,...

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals to Present at “Bioscience Pipeline & Innovation in Connecticut in the Age of COVID” Conference

NEW HAVEN, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies,...

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma

CD38-Targeting Molecule To be Evaluated in Multiple Patient Populations

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients

The Grant from the Bill & Melinda Gates Foundation Accelerates Company’s Efforts to Enter Clinical Trials by Early 2021

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma

Synergistic Potential of Kleo’s Antibody Recruiting Molecule (ARM™) and Celularity’s Placental-Derived NK Cells to Be Evaluated in the Context of COVID-19 and Multiple Myeloma

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)
Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting

Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT

BHVN : 40.69 (+1.98%)
PPTDF : 13.1100 (+38.00%)

Key Turning Points

3rd Resistance Point 13.1150
2nd Resistance Point 13.1140
1st Resistance Point 13.1120
Last Price 13.1100
1st Support Level 13.1090
2nd Support Level 13.1080
3rd Support Level 13.1060

See More

52-Week High 13.1130
Last Price 13.1100
Fibonacci 61.8% 10.9306
Fibonacci 50% 10.2565
Fibonacci 38.2% 9.5824
52-Week Low 7.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar